Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Chan

Showing results (181-190 of 263) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2012
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumorsLee S Rosen, Igor Puzanov, Gregory Friberg, et al.
Journal of Medicinal Chemistry|April 18, 2012
Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactionsRobert A Heald, Philip Jackson, Pascal Savy, et al.
International Journal of Cancer|April 11, 2016
Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147Amanda I Phipps, Qian Shi, Paul J Limburg, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Clinical Colorectal Cancer|April 10, 2010
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancerBert H O'Neil, Laura Raftery, Benjamin F Calvo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerScott Kopetz, Jayesh Desai, Emily Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid TumorsDavid S Hong, Patricia LoRusso, Omid Hamid, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 12, 2025
DNA Methylation-Based Classification of Kidney NeoplasmsAntonios Papanicolau-Sengos, Omkar Singh, Kyung Park, et al.
American Journal of Human Genetics|March 26, 2004
MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese populationTsun Leung Chan, Yee Wai Chan, Judy W C Ho, et al.
Pageof 27

Showing results (181-190 of 263) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2012
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumorsLee S Rosen, Igor Puzanov, Gregory Friberg, et al.
Journal of Medicinal Chemistry|April 18, 2012
Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactionsRobert A Heald, Philip Jackson, Pascal Savy, et al.
International Journal of Cancer|April 11, 2016
Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147Amanda I Phipps, Qian Shi, Paul J Limburg, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Clinical Colorectal Cancer|April 10, 2010
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancerBert H O'Neil, Laura Raftery, Benjamin F Calvo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerScott Kopetz, Jayesh Desai, Emily Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2018
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid TumorsDavid S Hong, Patricia LoRusso, Omid Hamid, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 12, 2025
DNA Methylation-Based Classification of Kidney NeoplasmsAntonios Papanicolau-Sengos, Omkar Singh, Kyung Park, et al.
American Journal of Human Genetics|March 26, 2004
MSH2 c.1452-1455delAATG is a founder mutation and an important cause of hereditary nonpolyposis colorectal cancer in the southern Chinese populationTsun Leung Chan, Yee Wai Chan, Judy W C Ho, et al.
Pageof 27